Research programme: peptide-drug conjugates - Phi Pharma
Latest Information Update: 25 Jul 2024
At a glance
- Originator Phi Pharma
- Developer Drugs for Neglected Diseases Initiative Foundation; HES-SO Valais-Wallis; Phi Pharma
- Class Antineoplastics; Drug conjugates; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute myeloid leukaemia; Leishmaniasis
Highest Development Phases
- Preclinical Acute myeloid leukaemia
- Research Solid tumours
- Discontinued Leishmaniasis
Most Recent Events
- 25 Jul 2024 peptide-drug conjugates is still in preclinical trials for Acute myeloid leukaemia in Switzerland (Parenteral) (Phi Pharma pipeline, July 2024)
- 25 Jul 2024 Discontinued for Leishmaniasis in Switzerland (unspecified route)
- 25 Jul 2024 Reaserch in Solid tumours in Switzerland (Parenteral), prior to July 2024 (Phi pharma pipeline, July 2024)